Experts in the field of obstetrics and gynecology recently met to discuss issues related to the epidemiology, diagnosis, and treatment of premenstrual syndrome/premenstrual dysphoric disorder (PMS/PMDD) in Latin American countries. The experts reviewed the existing accepted guidelines related to these issues and discussed adaptations to the diagnostic criteria and treatment recommendations in order to meet the specific needs of women in Latin American countries. This manuscript provides an overview of key information presented at this meeting and provides an up-to-date assessment of emerging treatment options covered in existing guidelines and treatment reviews. In addition, we discuss the relevance and possible application of this expanded knowledge to Latin American countries and provide practical recommendations for the diagnosis and management of PMS/PMDD in this setting. © 2007 Adis Data Information BV. All rights reserved.155263277Hylan, T.R., Sundell, K., Judge, R., The impact of premenstrual symptomatology on functioning and treatment seeking behaviour: Experience from the United States, United Kingdom and France (1999) J Womens Health Gend Based Med, 8, pp. 1043-1052Gise, L.H., Kase, N.G., Berkowitz, R.L., Contemporary issues in obstetrics and gynaecology (1988) The premenstrual syndromes, 2. , New York: Churchill LivingstoneHalbreich, U., Borenstein, J., Pearlstein, T., The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD) (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 1-23Johnson, S.R., The epidemiology and social impact of premenstrual symptoms (1987) Clin Obstet Gynecol, 30 (2), pp. 367-376American College of Obstetricians and Gynecologists. Premenstrual syndrome. Washington, DC: National Guideline Clearinghouse, 2000(1994) Diagnostic and statistical manual of mental disorders, , American Psychiatric Association, 4th ed. Washington, DC: American Psychiatric AssociationPerspectives on PMS/PMDD. Latin America Experts Group meeting2007 Jan 24-26Cancun, MexicoAndersch, B., Wenderstan, C., Hahn, L., Premenstrual complaints: 1. Prevalence of premenstrual symptoms in a Swedish urban population (1986) J Psychosom Obstet Gynaecol, 5, pp. 39-49Ramcharan, S., Love, E.J., Fick, G.H., The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors (1992) J Clin Epidemiol, 45 (4), pp. 377-392Di Giulio, G., Reissing, E.D., Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies (2006) J Psychosom Obstet Gynaecol, 27 (4), pp. 201-210Backström, T., Buchwald, S., The prevalence of PMS and PMDD and the awareness of associated terminology among women of reproductive age in European and Latin American countries [poster] (2005) World Congress of Human Reproduction, , Mar 10-13VeniceBackström, T., PMS and PMDD symptoms have a negative impact on daily life activities and quality of life among women in European and Latin American countries [oral presentation] (2005) World Congress of Human Reproduction, , Mar 10-13VeniceDean, B.B., Borenstein, J.E., A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome (2004) J Occup Environ Med, 46 (7), pp. 649-656PMS/PMDD negatively affects daily life activities. Pharmacoeconomics Outcomes News 2005476: 3-4Borenstein, J., Chiou, C.F., Dean, B., Estimating direct and indirect costs of premenstrual syndrome (2005) J Occup Environ Med, 47 (1), pp. 26-33Borenstein, J.E., Dean, B.B., Endicott, J., Health and economic impact of the premenstrual syndrome (2003) J Reprod Med, 48 (7), pp. 515-524Endicott, J., Nee, J., Harrison, W., Daily Record of Severity of Problems (DRSP): Reliability and validity (2006) Ach Womens Ment Health, 9 (1), pp. 41-49Halbreich, U., The etiology, biology, and evolving pathology of premenstrual syndromes (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 55-99Dalton, K., Dalton, M.E., Guthrie, K., Incidence of the premenstrual syndrome in twins (1987) BMJ, 295 (6605), pp. 1027-1028Johnson, S.R., Premenstrual syndrome, premenstrual dysphoric disorder, and be yond: A clinical primer for practitioners (2004) Obstet Gynecol, 104 (4), pp. 845-859Facchinetti, F., Genazzani, A.D., Martignoni, E., Neuroendocrine changes in luteal function in patients with premenstrual syndrome (1993) Clin Endocrinol Metab, 76 (5), pp. 1123-1127Schmidt, P.J., Nieman, L.K., Danaceau, M.A., Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome (1998) N Engl J Med, 338 (4), pp. 209-216Oelkers, W.K., Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure (1996) Steroids, 61 (4), pp. 166-171Chrousos, G.P., Torpy, D.J., Gold, P.W., Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: Clinical implications (1998) Ann Intern Med, 129 (3), pp. 229-240Cerin, A., Collins, A., Landgren, B.M., Hormonal and biochemical profiles of premenstrual syndrome: Treatment with essential fatty acids (1993) Acta Obstet Gynecol Scand, 72 (5), pp. 337-343Halbreich, U., Rojansky, N., Palter, S., Estrogen augments serotonergic activity in postmenopausal women (1995) Biol Psychiatry, 37 (7), pp. 434-441Matsumoto, A., Arai, Y., Osanai, M., Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats (1985) Neurosci Res, 2 (5), pp. 412-418McEwen BS, Alves SE, Bulloch K. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997485 Suppl. 7: 8-15De Ronchi, D., Muro, A., Marziani, A., Personality disorders and depressive symptoms in late luteal phase dysphoric disorder (2000) Psychother Psychosom, 69 (1), pp. 27-34Harlow, B.L., Cohen, L.S., Otto, M.W., Prevalence and predictors of depressive symptoms in older premenstrual women: The Harvard Study of Moods and Cycles (1999) Arch Gen Psychiatr, 56 (5), pp. 418-424Hendrick, V., Altshuler, L.L., Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter] (1998) J Clin Psychiatry, 59 (9), pp. 479-480Brawman-Mintzer, O., Shriqui, C., Biological basis of generalized anxiety disorder (1997) J Clin Psychiatry, 58 (SUPPL. 3), pp. 16-25Parry, B.L., Rosenthal, N.E., Tamarkin, L., Treatment of a patient with seasonal premenstrual syndrome (1987) Am J Psychiatry, 144 (6), pp. 762-766Praschak-Rieder, N., Willeit, M., Neumeister, A., Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder (2001) J Affect Disord, 63 (1-3), pp. 239-242Deuster, P.A., Adera, T., South-Paul, J., Biological, social, and behavioral factors associated with premenstrual syndrome (1999) Arch Fam Med, 8 (2), pp. 122-128Perkonigg, A., Yonkers, K.A., Pfister, H., Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder (2004) J Clin Psychiatry, 65 (10), pp. 1314-1322Campbell, E.M., Peterkin, D., O'Grady, K., Premenstrual symptoms in general practice patients: Prevalence and treatment (1997) J Reprod Med, 42 (10), pp. 637-646Severino, S.K., Moline, M.L., Premenstrual syndrome (1990) Obstet Gynecol Clin North Am, 17 (4), pp. 889-903Prior, J.C., Vigna, Y., Sciarretta, D., Conditioning exercise decreases premenstrual symptoms: A prospective, controlled 6-month trial (1987) Fertil Steril, 47 (3), pp. 402-408Steege, J.F., Blumenthal, J.A., The effects of aerobic exercise on premenstrual symp toms in middle-aged women: A preliminary study (1993) J Psychosom Res, 37 (2), pp. 127-133Freeman, E.W., Stout, A.L., Endicott, J., Treatment of premenstrual syndrome with a carbohydrate-rich beverage (2002) Int J Gynaecol Obstet, 77 (3), pp. 253-254Sayegh, R., Schiff, I., Wurtman, J., The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome (1995) Obstet Gynecol, 86 (4 PART 1), pp. 520-528Wyatt, K.M., Dimmock, P.W., Jones, P.W., Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review (1999) BMJ, 318 (7195), pp. 1375-1381Thys-Jacobs, S., Starkey, P., Bernstein, D., Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group (1998) Am J Obstet Gynecol, 179 (2), pp. 444-452Quaranta, S., Buscaglia, M.A., Meroni, M.G., Pilot study of the efficacy and safety of a modified-release magnesium 250mg tablet (Sincromag) for the treatment of premenstrual syndrome (2007) Clin Drug Investig, 27 (1), pp. 51-58Facchinetti, F., Borella, P., Sances, G., Oral magnesium successfully relieves premenstrual mood changes (1991) Obstet Gynecol, 78 (2), pp. 177-181Facchinetti, F., Sances, G., Borella, P., Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium (1991) Headache, 31 (5), pp. 298-301Berger, D., Schaffner, W., Schrader, E., Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS) (2000) Arch Gynecol Obstet, 264 (3), pp. 150-153Stevinson, C., Ernst, E., A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome (2000) BJOG, 107 (7), pp. 870-876Christensen, A.P., Oei, T.P., The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes (1995) J Affect Disord, 33 (1), pp. 57-63Hunter, M.S., Ussher, J.M., Browne, S., A randomized comparison of psychological (cognitive behavioural therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder (2002) Psychosom Obstet Gynaecol, 23 (3), pp. 193-199Hunter, M.S., Ussher, J.M., Cariss, M., Medical (Fluoxetine) and psychological (cognitive behavioural therapy) treatment for premenstrual dysphoric disorder: A study of treatment processes (2002) J Psychosom Res, 53 (3), pp. 811-817Rapkin, A., A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 39-53Smith, S., Rinehart, J.S., Ruddock, V.E., Treatment of premenstrual syndrome with alprazolam: Results of a double-blind, placebo-controlled, randomized crossover clinical trial (1987) Obstet Gynecol, 70 (1), pp. 37-43Freeman, E.W., Rickels, K., Sondheimer, S.J., A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome (1995) JAMA, 274 (1), pp. 51-57Evans, S.M., Haney, M., Levin, F.R., Mood and performance changes in women with premenstrual dysphoric disorder: Acute effects of alprazolam (1998) Neuropsychopharmacology, 19 (6), pp. 499-516Schmidt, P.J., Grover, G.N., Rubinow, D.R., Alprazolam in the treatment of premenstrual syndrome: A double-blind, placebo-controlled trial (1993) Arch Gen Psychiatry, 50 (6), pp. 467-473Landen, M., Eriksson, O., Sundblad, C., Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: A comparison of buspirone, nefazodone and placebo (2001) Psychopharmacology (Berl), 155 (3), pp. 292-298Bancroft, J., Boyle, H., Warner, P., The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes (1987) Clin Endocrinol (Oxf), 27 (2), pp. 171-182Brown, C.S., Ling, F.W., Andersen, R.N., Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial (1994) Obstet Gynecol, 84 (5), pp. 779-786Di Carlo, C., Palomba, S., Tommaselli, G.A., Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome (2001) Fertil Steril, 75 (2), pp. 380-384Freeman, E.W., Sondheimer, S.J., Rickels, K., Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study (1997) Psychopharmacol Bull, 33 (2), pp. 303-309Leather, A.T., Studd, J.W., Watson, N.R., The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: A placebo-controlled study (1999) Gynecol Endocrinol, 13 (1), pp. 48-55Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 199172 (2): 252A-FSundstrom, I., Nyberg, S., Bixo, M., Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen (1999) Acta Obstet Gynecol Scand, 78 (10), pp. 891-899West, C.P., Hillier, H., Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome (1994) Hum Reprod, 9 (6), pp. 1058-1063Wyatt, K.M., Dimmock, P.W., Ismail, K.M., The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: A meta analysis (2004) Bjog, 111 (6), pp. 585-593Deeny, M., Hawthorn, R., McKay Hart, D., Low dose danazol in the treatment of the premenstrual syndrome (1991) Postgrad Med J, 67 (787), pp. 450-454Hahn, P.M., Van Vugt, D.A., Reid, R.L., A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome (1995) Psychoneuroendocrinology, 20 (2), pp. 193-209Halbreich, U., Rojansky, N., Palter, S., Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes (1991) Fertil Steril, 56 (6), pp. 1066-1069Sarno Jr, A.P., Miller Jr, E.J., Lundblad, E.G., Premenstrual syndrome: Beneficial effects of periodic, low-dose danazol (1987) Obstet Gynecol, 70 (1), pp. 33-36Watts, J.F., Butt, W.R., Logan Edwards, R., A clinical trial using danazol for the treatment of premenstrual tension (1987) Br J Obstet Gynaecol, 94 (1), pp. 30-34Frackiewicz, E.J., Shiovitz, T.M., Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder (2001) J Am Pharm Assoc (Wash), 41 (3), pp. 437-447Dimmock, P.W., Wyatt, K.M., Jones, P.W., Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review (2000) Lancet, 356 (9236), pp. 1131-1136Cohen, L.S., Miner, C., Brown, E.W., Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries (2002) Obstet Gynecol, 100 (3), pp. 435-444Menkes, D.B., Taghavi, E., Mason, P.A., Fluoxetine's spectrum of action in premenstrual syndrome (1993) Int Clin Psychopharmacol, 8 (2), pp. 95-102Miner, C., Brown, E., McCray, S., Weekly luteal-phase dosing with enteric coated fluoxetine 90mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial (2002) Clin Ther, 24 (3), pp. 417-433Pearlstein, T.B., Stone, A.B., Lund, S.A., Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder (1997) J Clin Psychopharmacol, 17 (4), pp. 261-266Steiner, M., Romano, S.J., Babcock, S., The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder (2001) BJOG, 108 (5), pp. 462-468Steiner, M., Steinberg, S., Stewart, D., Fluoxetine in the treatment of premenstrual dysphoria: Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group (1995) N Engl J Med, 332 (23), pp. 1529-1534Stone, A.B., Pearlstein, T.B., Brown, W.A., Fluoxetine in the treatment of late luteal phase dysphoric disorder (1991) J Clin Psychiatry, 52 (7), pp. 290-293Su, T.P., Schmidt, P.J., Danaceau, M.A., Fluoxetine in the treatment of premenstrual dysphoria (1997) Neuropsychopharmacology, 16 (5), pp. 346-356Wood, S.H., Mortola, J.F., Chan, Y.F., Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study (1992) Obstet Gynecol, 80 (3 PART 1), pp. 339-344Cohen, L.S., Soares, C.N., Yonkers, K.A., Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial (2004) Psychosom Med, 66 (5), pp. 707-713Freeman, E.W., Rickels, K., Arredondo, F., Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant (1999) J Clin Psychopharmacol, 19 (1), pp. 3-8Freeman, E.W., Rickels, K., Sondheimer, S.J., Differential response to antidepres sants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial (1999) Arch Gen Psychiatry, 56 (10), pp. 932-939Freeman, E.W., Rickels, K., Sondheimer, S.J., Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder (2004) Am J Psychiatry, 161 (2), pp. 343-351Halbreich, U., Bergeron, R., Yonkers, K.A., Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder (2002) Obstet Gynecol, 100 (6), pp. 1219-1229Jermain, D.M., Preece, C.K., Sykes, R.L., Luteal phase sertraline treatment for premenstrual dysphoric disorder: Results of a double-blind, placebo-controlled, crossover study (1999) Arch Fam Med, 8 (4), pp. 328-332Pearlstein, T.B., Halbreich, U., Batzar, E.D., Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo (2000) J Clin Psychiatry, 61 (2), pp. 101-109Steiner, M., Hirschberg, A.L., Bergeron, R., Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder (2005) Am J Obstet Gynecol, 193 (2), pp. 352-360Yonkers, K.A., Gullion, C., Williams, A., Paroxetine as a treatment for premenstrual dysphoric disorder (1996) J Clin Psychopharmacol, 16 (1), pp. 3-8Yonkers, K.A., Halbreich, U., Freeman, E., Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group (1997) JAMA, 278 (12), pp. 983-988Yonkers, K.A., Halbreich, U., Freeman, E., Sertraline in the treatment of premenstrual dysphoric disorder (1996) Psychopharmacol Bull, 32 (1), pp. 41-46Freeman, E.W., Jabara, S., Sondheimer, S.J., Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study (2002) J Womens Health Gend Based Med, 11 (5), pp. 459-464Wikander, I., Sundblad, C., Andersch, B., Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? (1998) J Clin Psychopharmacol, 18 (5), pp. 390-398Freeman, E.W., Sondheimer, S.J., Sammel, M.D., A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder (2005) J Clin Psychiatry, 66 (6), pp. 769-773Sundblad, C., Hedberg, M.A., Eriksson, E., Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial (1993) Neuropsychopharmacology, 9 (2), pp. 133-145Sundblad, C., Modigh, K., Andersch, B., Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo-controlled trial (1992) Acta Psychiatr Scand, 85 (1), pp. 39-47Ferguson, J.M., SSRI antidepressant medications: Adverse effects and tolerability (2001) Prim Care Companion J Clin Psychiatry, 3 (1), pp. 22-27Sundstrom-Poromaa, I., Bixo, M., Bjorn, I., Compliance to antidepressant drug therapy for treatment of premenstrual syndrome (2000) J Psychosom Obstet Gynaecol, 21 (4), pp. 205-211Graham, C.A., Sherwin, B.B., A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive (1992) J Psychosom Res, 36 (3), pp. 257-266Backstrom, T., Hansson-Malmstrom, Y., Lindhe, B.-A., Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations (1992) Contraception, 46, pp. 253-268O'Brien, P.M., Craven, D., Selby, C., Treatment of premenstrual syndrome by spironolactone (1979) Br J Obstet Gynaecol, 86 (2), pp. 142-147Burnet, R.B., Radden, H.S., Easterbrook, E.G., Premenstrual syndrome and spironolactone (1991) Aust N Z J Obstet Gynaecol, 31 (4), pp. 366-368Borenstein, J., Yu, H.T., Wade, S., Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life (2003) J Reprod Med, 48 (2), pp. 79-85Foidart, J.M., Wuttke, W., Bouw, G.M., A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel (2000) Eur J Contracept Reprod Health Care, 5 (2), pp. 124-134Freeman, E.W., Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder (2002) Eur J Contracept Reprod Health Care, 7 (SUPPL. 3), pp. 27-34,42-43Pearlstein, T.B., Bachmann, G.A., Zacur, H.A., Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation (2005) Contraception, 72 (6), pp. 414-421Sangthawan, M., Taneepanichskul, S., A comparative study of monophasic oral contraceptives containing either drospirenone 3mg or levonorgestrel 150 microg on premenstrual symptoms (2005) Contraception, 71 (1), pp. 1-7Sillem, M., Schneidereit, R., Heithecker, R., Use of an oral contraceptive containing drospirenone in an extended regimen (2003) Eur J Contracept Reprod Health Care, 8 (3), pp. 162-169Yonkers, K.A., Brown, C., Pearlstein, T.B., Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder (2005) Obstet Gynecol, 106 (3), pp. 492-501Sullivan, H., Furniss, H., Spona, J., Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity (1999) Fertil Steril, 72 (1), pp. 115-120Sulak, P.J., Scow, R.D., Preece, C., Hormone withdrawal symptoms in oral contraceptive users (2000) Obstet Gynecol, 95 (2), pp. 261-266Sociedad Española de Ginecología y Obstetricia (SEGO). Algoritmo terapéutico Síndrome Premenstrual. Documento de Consenso de la Sociedad Española de Ginecología y Obstetricia [online]. Available from URL: http://www.sego.es [Accessed 2007 Sep 19]Foidart, J.M., Added benefits of drospirenone for compliance (2005) Climacteric, 8 (SUPPL. 3), pp. 28-34Gruber, D.M., Huber, J.C., Melis, G.B., A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug (2006) Treat Endocrinol, 5 (2), pp. 115-121Schultz-Zehden, B., Boschitsch, E., User experience with an oral contraceptive containing ethinylestradiol 30mug and drospirenone 3mg (Yasmin®) in clinical practice (2006) Treat Endocrinol, 5 (4), pp. 251-256